Latest Commentary

We're looking for 2014's Fiercest women in biotech

Our annual top women in biotech report spotlights women in the life sciences industry, academia and regulatory roles who are outstanding members of the field. Our nomination form for this year's...

Biosimilars set to boom as new patent cliff on biologic superstars looms

If you look at the biosimilars market as a global whole, the sum total of revenue generated by the follow-on crowd just barely crossed into blockbuster territory in 2013, according to a new study from Allied Marketing Research. But that $1.3 billion base is expected to swell to $35 billion by 2020 as new products penetrate the market in North America, Europe and Asia.

After a taste of disaster, Reata plans a comeback for bardoxolone

Close to four years ago, Reata Pharmaceuticals scored one of the biggest packages of upfront and near-term cash the industry had seen at that point. AbbVie signed up to partner on its chronic kidney drug bardoxolone by dangling $450 million in quick cash, and then came back a year later to get the full portfolio of follow-up drugs at Reata for another $400 million upfront.

Taking the pulse of partnering at BIO 2014

Whether it's in Boston, Chicago, Philadelphia or Washington, DC, the centerpiece of the annual BIO convention is always the same: a sprawl of interconnecting cubicles and makeshift corridors where would-be dealmakers shake hands, make promises and hope to form pacts that'll turn their strategic plans into reality.

John Carroll wins the European Mediscience 'Commentator of the Year' award

I am pleased to announce FierceBiotech's own Editor-in-Chief John Carroll has won the award for "Commentator of the Year" from the European Mediscience Awards in London on June 19,...

What's next in diabetes drugs? The pulse of R&D at ADA14

Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.

Can Orexigen and its partner Takeda escape the weight-drug jinx?

If Orexigen wins FDA approval for its weight loss drug NB32 (which used to be called Contrave) by tomorrow's long-awaited PDUFA date--and the odds are in its favor--look for the biotech and its pharma partner Takeda to barrel into a huge obesity market that has provided a chilly reception for a pair of rivals.

The search is on for 2014's Fiercest biotech startups

Like we always do about this time of year, FierceBiotech is kicking off its search for the next class of Fierce 15 companies, and we want to hear from you. It's easy: Just fill out the form embedded below or find it here.

FierceBiotech and the experts weigh in on surviving the proof-of-concept challenge

Drug development has never been easy, but it is doable. And some expert advice always helps. On June 18, bright and early, John Carroll will be in San Diego to moderate a panel discussion on this topic. You can click here to register for the event.

Checking in on Big Pharma's big immuno-oncology race

On Sunday, FierceBiotech's Damian Garde (@DamianFierce) and ISI analyst Mark Schoenebaum (@MarkSchoenebaum) discussed a promising crop of new cancer-fighting immunotherapies under the spotlight...